Inhibrx Profit Margin 2020-2022 | INBX

Current and historical gross margin, operating margin and net profit margin for Inhibrx (INBX) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Inhibrx net profit margin as of March 31, 2022 is -1289.14%.
Inhibrx Annual Profit Margins
Inhibrx Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.516B $0.007B
Inhibrx Inc. is a clinical-stage biotechnology company. The company's pipeline is focused on oncology and orphan diseases. Inhibrx Inc. is based in SAN DIEGO.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.299B 9.94
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.420B 16.45
Biohaven Pharmaceutical Holding (BHVN) United States $10.085B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.716B 0.00
Emergent Biosolutions (EBS) United States $1.842B 7.89
Arcus Biosciences (RCUS) United States $1.368B 34.69
Myovant Sciences (MYOV) United Kingdom $0.984B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.517B 0.00
Gelesis Holdings (GLS) United States $0.358B 0.00
Zymeworks (ZYME) Canada $0.354B 0.00
Ambrx Biopharma (AMAM) United States $0.157B 0.00
Enzo Biochem (ENZ) United States $0.117B 24.10
SQZ Biotechnologies (SQZ) United States $0.095B 0.00